OBJECTIVES: To evaluate the quality of life (QoL) of CML patients using the EQ-5D-5L instrument by gathering the patient’s perspective of how, and to what extent, their therapy impacts QoL. METHODS: Patients from the Huntsman Cancer Institute completed the EQ-5D-5L. Inclusion criteria were current chronic phase of CML, visits after June 2012, and age ≥ 18 years at diagnosis. The analysis included descriptive statistics of the sample population and derivation of a utility value for each patient. Kruskal Wallis test was conducted to compare the utility values for non-parametric data, and t test was conducted for parametric data. A utility value of 0 implies death, while a value of 1 implies full health. RESULTS: Out of the 81 questionnaires that were mailed 33 (40.7%) were returned.  Three returned questionnaires were excluded due to failure to complete the instrument, and one patient passed away. Of the 29 patients in the final sample, there are 15 males, the mean age was 54.3±15.0 years, the mean utility was 0.79±0.15, and the mean duration of CML was 5.1±3.6 years. For current CML treatments, 3 patients had undergone stem cell transplantation (SCT), 25 patients were receiving tyrosine kinase inhibitors (TKIs), and one patient discontinued medication due to adverse events. Overall, the mean utility difference between SCT and TKIs was not statistically significant (0.72± 0.15 vs. 0.80 ± 0.15, p=0.35). Among TKIs, Imatinib had the highest utility scores (0.88±0.14, n=10), followed by ponatinib (0.83±0.15, n=3), nilotinib (0.81±0.04, n=3), dasatinib (0.72±0.12, n=8), and bosutinib (0.48, n=1). There was no statistical difference in utilities in patients who received one line of treatment (0.83±0.15, n=13) vs. multiple lines (0.76±0.15, n=12, p=0.22). CONCLUSIONS: Although the study population was small, our results indicate that current US CML patients have good QoL scores. A larger sample size is needed for further research.